Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: Comparison with inogatran

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 1, 2001, Pages 19-31

  Chi, Liguo ^a   Mertz, Thomas E ^a   Rogers, Karen L ^a   Janiczek, Nancy ^a   Peng, Yun Wen ^a   Saganek, Lori ^a   Bousley, Richard F ^a   Juneau, Paul L ^a   Uprichard, Andrew C G ^a   Gallagher, Kim P ^a  

^a PFIZER INC   (United States)

Author keywords

Antithrombotics; Inogatran; LB 30057; Rabbit; Thrombin inhibitors; Thrombosis

Indexed keywords

(S) 4 [3 (CYCLOPENTYLMETHYLAMINO)2 [(2 NAPHTHALENYLSULFONYL)AMINO] 3 OXOPROPYL]BENZENECARBOXIMIDIC ACID HYDRAZIDE; CI 1028; INOGATRAN; LB 30057; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CAVA VEIN; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EXPERIMENTAL MODEL; GRAVIMETRY; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; SPECIES DIFFERENCE; THROMBIN TIME; THROMBOGENESIS; THROMBOSIS; VEIN BLOOD FLOW; WEIGHT;

ANIMALS; BENZAMIDES; BLEEDING TIME; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; GLYCINE; HEMOSTASIS; IMPLANTS, EXPERIMENTAL; INJECTIONS; PIPERIDINES; RABBITS; REGIONAL BLOOD FLOW; THROMBIN; THROMBOSIS; VENA CAVA, SUPERIOR;

EID: 0035061634     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008900109285     Document Type: Article

References (35)

1. Pharmacology of heparin and oral anticoagulants
2. Advances in anti-thrombotic therapy: Novel agents
3. The therapeutic potential of novel anticoagulants
4. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside
5. Direct thrombin inhibitors in cardiovascular medicine
6. Potential advantages of direct-acting thrombin inhibitors
7. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation
8. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
9. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
10. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
11. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
12. Optimal dose-finding of recombinant hirudin, CGP 39393, desirudin (Revasc), in patients undergoing total hip replacement
13. Direct thrombin inhibitors: Appraisal of the antithrombotic/haemorrhagic balance
14. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
15. Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor
16. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma
17. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective anti-thrombotic agent in rodent models of arterial and venous thrombosis - Comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban
18. Effects of the synthetic thrombin inhibitor argatroban on fibrinor clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
19. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis
20. Discovery of a highly selective, orally bioavailable, direct thrombin inhibitor, LB30057
21. The antithrombotic effects of LB-30057 in the canine model of electrolytically-induced venous thrombosis
22. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis
23. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time
24. A novel model of venous thrombosis in the vena cava of rabbits
25. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
26. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis
27. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions
28. Does low molecular weight heparin cause less bleeding?
29. In vitro properties of inogatran, a new selective low molecular weight inhibitor of thrombin
30. Comparison of in vitro and in vivo properties of r-hirudin (HBW 023) and a synthetic analogous peptide
31. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease
32. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis
33. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: Comparison with an ex vivo annular perfusion chamber model
34. A critical reappraisal of the bleeding time
35. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody